newsfilter
← Latest News
Business Wire·

JAMP and Alvotech Announce Canadian Approval of SIMLANDI™, a High-Concentration Biosimilar to Humira®, Providing Access to Previously Unavailable Versions in Canada

Health Canada rules that 40 mg/0.4 mL and 80 mg/0.8 mL presentations of SIMLANDI™ are not subject to the statutory stay, clearing the way for the launch in the Canadian market High-concentration formulations, previously unavailable in Canada, refle